Glenmark Pharmaceuticals launches 3-in-1 inhaler therapy AIRZ-FF for COPD in India

AIRZ-FF has been exclusively studied in the Indian population and introduced to address challenges faced by a significant portion of COPD patients in the country. COPD is a very common, serious, and debilitating lung disease which like hypertension or diabetes, requires personalized treatment over the rest of the patient's life.

India is currently home to more than 55.3 million people living with COPD of varying degrees of severity. The disease prevalence has grown significantly by 24% in the last decade alone. Health experts attribute this rise to low levels of awareness and low rates of diagnosis of the disease. Together these factors have made COPD the second leading cause of death by disease in India.

"COPD poses a significant public health challenge in India for many reasons. When it comes to treatment, there is poor patient compliance and adherence to prescribed doses, owing to the need for multiple inhalers through the day. By introducing AIRZ-FF, we hope to reduce this burden for patients, by delivering three effective therapies together in the same inhaler," said Sujesh Vasudevan, President, India Formulations, Middle East, and Africa at Glenmark Pharmaceuticals.

He added, "Glenmark continues to invent and innovate healthcare solutions that meet specific and often hard-to-address needs of patients in India and the world." 

Read also: Glenmark gets DCGI nod for Clinical Trials on Favipiravir Antiviral tablets for COVID-19 patients in India